AR084032A1 - Compuesto biciclico - Google Patents
Compuesto biciclicoInfo
- Publication number
- AR084032A1 AR084032A1 ARP110104436A ARP110104436A AR084032A1 AR 084032 A1 AR084032 A1 AR 084032A1 AR P110104436 A ARP110104436 A AR P110104436A AR P110104436 A ARP110104436 A AR P110104436A AR 084032 A1 AR084032 A1 AR 084032A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- optionally substituted
- aromatic ring
- nitrogen atom
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente proporciona un compuesto que tiene una acción inhibidora de ACC, que es de utilidad como un agente para la prevención o el tratamiento de obesidad, diabetes, y similares y que tiene una eficacia superior. Composición farmacéutica.Reivindicación 1: Un compuesto representado por la fórmula (1) caracterizado porque R1 es un grupo representado por la fórmula: -COR2, en donde R2 es un átomo de nitrógeno o un sustituyente o un grupo de anillo aromático de 5 ó 6 miembros opcionalmente sustituido; R3 es un grupo alquilo C1-6 opcionalmente sustituido con átomos de halógeno o un grupo cicloalquilo C3-6 opcionalmente sustituido; R4a y R4b son, de modo independiente, un átomo de nitrógeno o un sustituyente; X es O, CO, CR5aR5b, en donde R5a y R5b son, de modo independiente, un átomo de nitrógeno o un sustituyente, NR5c, en donde R5c es un átomo de nitrógeno o un grupo alquilo C1-6 opcionalmente sustituido, S, SO o S(O)2; el anillo A es un anillo aromático de 5 ó 6 miembros también opcionalmente sustituido; para el anillo P y el anillo Q, (i) el anillo P es un anillo aromático de 5 miembros también opcionalmente sustituido, el anillo Q es un anillo aromático de 6 miembros también opcionalmente sustituido y el anillo P y el anillo Q se fusionan para formar un anillo aromático bicíclico también opcionalmente sustituido o (ii) el anillo P es un anillo no aromático de 5 miembros también opcionalmente sustituido, el anillo Q es un anillo aromático de 6 miembros también opcionalmente sustituido y el anillo P y el anillo Q se fusionan para formar un anillo no aromático bicíclico también opcionalmente sustituido; y R6 es un grupo alquilo C1-6 opcionalmente sustituido o un grupo cicloalquilo C3-6 opcionalmente sustituido; o una de sus sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010266097 | 2010-11-30 | ||
| JP2011175330 | 2011-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084032A1 true AR084032A1 (es) | 2013-04-17 |
Family
ID=45418740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104436A AR084032A1 (es) | 2010-11-30 | 2011-11-29 | Compuesto biciclico |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8729102B2 (es) |
| EP (1) | EP2649062B1 (es) |
| JP (1) | JP5824517B2 (es) |
| KR (1) | KR20140001965A (es) |
| CN (1) | CN103347872B (es) |
| AR (1) | AR084032A1 (es) |
| AU (1) | AU2011337565A1 (es) |
| BR (1) | BR112013013417A2 (es) |
| CA (1) | CA2819400A1 (es) |
| CL (1) | CL2013001520A1 (es) |
| CO (1) | CO6751239A2 (es) |
| CR (1) | CR20130281A (es) |
| DO (1) | DOP2013000118A (es) |
| EA (1) | EA201390794A1 (es) |
| EC (1) | ECSP13012719A (es) |
| ES (1) | ES2536319T3 (es) |
| MA (1) | MA34713B1 (es) |
| MX (1) | MX2013006113A (es) |
| PE (1) | PE20140161A1 (es) |
| PH (1) | PH12013501099A1 (es) |
| SG (1) | SG190925A1 (es) |
| TW (1) | TW201242951A (es) |
| UY (1) | UY33756A (es) |
| WO (1) | WO2012074126A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201206911A (en) | 2010-04-27 | 2012-02-16 | Takeda Pharmaceutical | Bicyclic compound |
| WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
| WO2014088983A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| PL403149A1 (pl) * | 2013-03-14 | 2014-09-15 | Celon Pharma Spółka Akcyjna | Nowe związki pochodne pirazolilobenzo[d]imidazolu |
| CA2911818A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| CA2911822A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| WO2014182943A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| EA030942B1 (ru) | 2013-05-10 | 2018-10-31 | Джилид Аполло, Ллс | Ингибиторы акк и их применение |
| MX2016002479A (es) | 2013-09-12 | 2016-05-31 | Pfizer | Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris. |
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| CA2957046C (en) | 2014-08-04 | 2022-11-15 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| CN104193731B (zh) * | 2014-08-27 | 2017-03-15 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
| CN107108534B (zh) | 2014-08-29 | 2023-05-09 | Chdi基金会股份有限公司 | 用于成像亨廷顿蛋白的探针 |
| JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| CN104447725B (zh) * | 2014-10-22 | 2018-02-02 | 浙江大学 | 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法 |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| AU2016332021A1 (en) * | 2015-09-29 | 2018-04-19 | Oncotherapy Science, Inc. | Bicyclic compound and use thereof for inhibiting SUV39H2 |
| CN105601626A (zh) * | 2015-11-04 | 2016-05-25 | 浙江大学 | 一种含2-取代噁唑啉衍生物的制备方法 |
| TWI824309B (zh) | 2015-11-06 | 2023-12-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
| ES2995198T3 (en) | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| IL270068B (en) | 2017-04-24 | 2022-06-01 | Tesaro Inc | Methods of manufacturing of niraparib |
| BR112020007593A2 (pt) | 2017-10-18 | 2020-09-24 | Incyte Corporation | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021124277A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US20250041279A1 (en) | 2021-11-19 | 2025-02-06 | Shionogi & Co., Ltd. | Therapeutic medicine for heart disease or skeletal muscle disease |
| AR129265A1 (es) | 2022-05-12 | 2024-08-07 | Syngenta Crop Protection Ag | Compuestos de alcoxi-heteroaril-carboxamida o tioamida |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| EP1027051B1 (en) * | 1997-04-30 | 2005-01-05 | Eli Lilly And Company | Antithrombotic agents |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| WO2001082925A1 (en) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonists |
| EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| AU2003254650B2 (en) * | 2002-07-24 | 2010-09-09 | Qlt, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| AR041867A1 (es) | 2002-11-01 | 2005-06-01 | Takeda Pharmaceutical | Agente para prevenir o tratar neuropatia |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| CA2507026A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, their production and use |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
| TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| WO2006112549A1 (ja) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | COMPOUND OF PHENOXYALKANOIC ACID |
| EP1912645A2 (en) | 2005-08-10 | 2008-04-23 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| WO2007095601A2 (en) * | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
| WO2008047821A1 (en) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| WO2008050821A1 (en) | 2006-10-19 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Indole compound |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| US8501804B2 (en) | 2008-10-27 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| WO2010118009A1 (en) * | 2009-04-06 | 2010-10-14 | Ptc Therapeutics, Inc. | Hcv inhibitor and therapeutic agent combinations |
| TW201206911A (en) | 2010-04-27 | 2012-02-16 | Takeda Pharmaceutical | Bicyclic compound |
| WO2012108478A1 (ja) | 2011-02-09 | 2012-08-16 | 武田薬品工業株式会社 | 単環化合物 |
-
2011
- 2011-11-29 CA CA2819400A patent/CA2819400A1/en not_active Abandoned
- 2011-11-29 JP JP2013524677A patent/JP5824517B2/ja not_active Expired - Fee Related
- 2011-11-29 TW TW100143674A patent/TW201242951A/zh unknown
- 2011-11-29 KR KR1020137016850A patent/KR20140001965A/ko not_active Withdrawn
- 2011-11-29 ES ES11802168.2T patent/ES2536319T3/es active Active
- 2011-11-29 EP EP11802168.2A patent/EP2649062B1/en active Active
- 2011-11-29 CN CN201180066388.XA patent/CN103347872B/zh not_active Expired - Fee Related
- 2011-11-29 AU AU2011337565A patent/AU2011337565A1/en not_active Abandoned
- 2011-11-29 US US13/306,069 patent/US8729102B2/en not_active Expired - Fee Related
- 2011-11-29 SG SG2013041546A patent/SG190925A1/en unknown
- 2011-11-29 MX MX2013006113A patent/MX2013006113A/es not_active Application Discontinuation
- 2011-11-29 WO PCT/JP2011/078010 patent/WO2012074126A1/en not_active Ceased
- 2011-11-29 EA EA201390794A patent/EA201390794A1/ru unknown
- 2011-11-29 PE PE2013001328A patent/PE20140161A1/es not_active Application Discontinuation
- 2011-11-29 PH PH1/2013/501099A patent/PH12013501099A1/en unknown
- 2011-11-29 BR BR112013013417A patent/BR112013013417A2/pt not_active IP Right Cessation
- 2011-11-29 UY UY0001033756A patent/UY33756A/es not_active Application Discontinuation
- 2011-11-29 AR ARP110104436A patent/AR084032A1/es not_active Application Discontinuation
-
2013
- 2013-05-29 DO DO2013000118A patent/DOP2013000118A/es unknown
- 2013-05-29 CL CL2013001520A patent/CL2013001520A1/es unknown
- 2013-06-05 MA MA35965A patent/MA34713B1/fr unknown
- 2013-06-11 CR CR20130281A patent/CR20130281A/es not_active Application Discontinuation
- 2013-06-24 CO CO13149620A patent/CO6751239A2/es not_active Application Discontinuation
- 2013-06-25 EC ECSP13012719 patent/ECSP13012719A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013006113A (es) | 2013-11-01 |
| US20120142714A1 (en) | 2012-06-07 |
| TW201242951A (en) | 2012-11-01 |
| JP2013545718A (ja) | 2013-12-26 |
| EA201390794A1 (ru) | 2013-11-29 |
| US8729102B2 (en) | 2014-05-20 |
| CL2013001520A1 (es) | 2013-10-18 |
| EP2649062A1 (en) | 2013-10-16 |
| AU2011337565A2 (en) | 2013-07-11 |
| UY33756A (es) | 2012-06-29 |
| CN103347872A (zh) | 2013-10-09 |
| SG190925A1 (en) | 2013-07-31 |
| ES2536319T3 (es) | 2015-05-22 |
| EP2649062B1 (en) | 2015-04-08 |
| KR20140001965A (ko) | 2014-01-07 |
| BR112013013417A2 (pt) | 2019-09-24 |
| PE20140161A1 (es) | 2014-02-19 |
| DOP2013000118A (es) | 2013-09-30 |
| JP5824517B2 (ja) | 2015-11-25 |
| PH12013501099A1 (en) | 2013-07-08 |
| WO2012074126A1 (en) | 2012-06-07 |
| CA2819400A1 (en) | 2012-06-07 |
| AU2011337565A1 (en) | 2013-07-11 |
| ECSP13012719A (es) | 2013-12-31 |
| WO2012074126A9 (en) | 2013-06-06 |
| CR20130281A (es) | 2013-10-07 |
| MA34713B1 (fr) | 2013-12-03 |
| CO6751239A2 (es) | 2013-09-16 |
| CN103347872B (zh) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084032A1 (es) | Compuesto biciclico | |
| ECSP14020586A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| MX344669B (es) | Agente antiplaquetas novedoso. | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201591586A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| CO6630189A2 (es) | Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10 | |
| UY34723A (es) | ?compuestos de 7-oxo-1,6-diazabiciclo[3.2.1]oct-3-en-6-ilo sustituidos para usarse como inhibidores de la betalactamasa?. | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
| PE20151071A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| PE20121695A1 (es) | 5-alquinil-pirimidinas | |
| AR080802A1 (es) | Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro | |
| PE20151892A1 (es) | Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas | |
| AR080969A1 (es) | Compuesto biciclico | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| PE20151142A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| UY32131A (es) | Compuestos de anillo fusionado y uso de los mismos | |
| BR112018003489A2 (pt) | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas | |
| BR112015020952A2 (pt) | compostos antivirais | |
| MX2016006509A (es) | Compuestos triciclicos de piperidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |